Elevation Oncology, Inc.
ELEV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | -0.00 | -0.05 |
| FCF Yield | -112.85% | -307.00% | -387.12% | -21.59% |
| EV / EBITDA | -0.31 | 0.02 | -0.06 | 0.21 |
| Quality | ||||
| ROIC | -49.09% | -53.53% | -120.52% | -22.78% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 1.23 | 0.90 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 35.27% | 34.35% | -183.65% | -143.89% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.46 | 0.17 | 4.57 |
| Interest Coverage | -11.18 | -10.90 | -197.39 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -8,501.46 | -4,745.00 | -86,004.81 | -114,528.89 |